• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT™ (Ligand Activated Therapy) platform technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT™ platform technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

Products & Possibilities

Our co-lead clinical development candidates are KP415 – a prodrug product of dexmethylphenidate (d-MPH) with potential improvements over existing extended-release ADHD treatments, and KP484 – a “super-extended release” d-MPH prodrug product for the treatment of ADHD in patients that require a very long duration of therapy.

In addition, we have gained approval of Apadaz®, an immediate-release, benzhydrocodone/acetaminophen combination product for the treatment of acute pain. 

Our Value Proposition

KemPharm® believes that its LAT™ Platform technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s pipeline consists of multiple programs targeting opportunities in ADHD, pain, and CNS indications.

We employ our LAT™ (Ligand Activated Therapy) platform technology to improve the attributes of approved drugs.

Learn more about LAT™

September 17, 2018

Featured Publication

KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug

NDA Filing for KP415 Anticipated As Soon As First Quarter of 2019 Following Successful Completion of HAP Program Highlights of KP415.A02 Intranasal HAP Trial Results: Mean Drug Liking (Emax) of intranasal KP415 Prodrug (serdexmethylphenidate) was statistically significantly lower than d-methylphenidate hydrochloride   Coralville, IA – September 17, 2018 –KemPharm, Inc. […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture

  • 11

    Oct

    18

  • KemPharm Provides Highlights from KOL Investo...

  • 05

    Oct

    18

  • KemPharm Announces Pricing of Public Offering...

  • 04

    Oct

    18

  • KemPharm Announces Proposed Public Offering o...